How Anticholinergic Drugs Might Promote Alzheimer's Disease: More Amyloid-β and Less Phosphatidylcholine.

Drugs that block muscarinic cholinergic neurotransmission in the brain can, as a consequence, increase the formation of amyloid-β, and decrease brain levels of phosphatidylcholine (by slowing its synthesis and accelerating its turnover). Both of these effects might cause a decrease in brain synapses, as characterizes and probably underlies the memory disorder of early Alzheimer's disease.

[1]  Sascha Dublin,et al.  Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. , 2015, JAMA internal medicine.

[2]  Cornelis J. Stam,et al.  The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer’s Disease: A Randomised Controlled Study , 2014, PloS one.

[3]  P. Kamphuis,et al.  A specific multi-nutrient diet reduces Alzheimer-like pathology in young adult AβPPswe/PS1dE9 mice. , 2012, Journal of Alzheimer's disease : JAD.

[4]  R. Wurtman,et al.  Plasma choline concentration varies with different dietary levels of vitamins B6, B12 and folic acid in rats maintained on choline-adequate diets , 2011, British Journal of Nutrition.

[5]  S. Zeisel,et al.  Choline intake and genetic polymorphisms influence choline metabolite concentrations in human breast milk and plasma. , 2010, The American journal of clinical nutrition.

[6]  R. Wurtman,et al.  Use of phosphatide precursors to promote synaptogenesis. , 2009, Annual review of nutrition.

[7]  A. Fisher.  Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease , 2008, Neurotherapeutics.

[8]  Phillip B. Jones,et al.  Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. , 2007, The American journal of pathology.

[9]  J. Fritschy,et al.  Matching of Pre- and Postsynaptic Specializations during Synaptogenesis , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[10]  George E. Marzloff,et al.  Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally , 2006, Brain Research.

[11]  R. Schliebs,et al.  Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein , 2006, International Journal of Developmental Neuroscience.

[12]  F. LaFerla,et al.  M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice , 2006, Neuron.

[13]  W. Oertel,et al.  Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimer's disease , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[14]  B. Slack,et al.  The m3 muscarinic acetylcholine receptor is coupled to mitogen-activated protein kinase via protein kinase C and epidermal growth factor receptor kinase. , 2000, The Biochemical journal.

[15]  J. Growdon,et al.  Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. , 1993, The Journal of biological chemistry.

[16]  J. Growdon,et al.  Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Growdon,et al.  Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.

[18]  J. Growdon,et al.  Evidence for a membrane defect in Alzheimer disease brain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[20]  R. Wurtman,et al.  Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum , 1989, Brain Research.

[21]  H. Ladinsky,et al.  Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine , 1986, British journal of pharmacology.

[22]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[23]  W. Millington,et al.  Choline Administration Elevates Brain Phosphorylcholine Concentrations , 1982, Journal of neurochemistry.

[24]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[25]  D M Bowen,et al.  Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. , 1976, Brain : a journal of neurology.

[26]  D. Drachman,et al.  Human memory and the cholinergic system. A relationship to aging? , 1974, Archives of neurology.

[27]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[28]  R. Wurtman,et al.  Choline and Its Products Acetylcholine and Phosphatidylcholine , 2009 .

[29]  I. Ferrer,et al.  Decreased numbers of dendritic spines on cortical pyramidal neurons in dementia. A quantitative Golgi study on biopsy samples. , 1988, Human neurobiology.

[30]  R. Wurtman,et al.  Phosphatidylcholine as a precursor of choline for acetylcholine synthesis. , 1987, Journal of neural transmission. Supplementum.

[31]  R. Wurtman,et al.  "Autocannibalism" of membrane choline-phospholipids: physiology and pathology. , 1986, Psychopharmacology bulletin.

[32]  R. Wurtman,et al.  Effects of electrical stimulation and choline availability on the release and contents of acetylcholine and choline in superfused slices from rat striatum. , 1985, Journal de physiologie.